BDF Gestion Makes New Investment in IDEXX Laboratories, Inc. $IDXX

BDF Gestion purchased a new stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 3,198 shares of the company’s stock, valued at approximately $1,670,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of IDXX. IFP Advisors Inc grew its stake in shares of IDEXX Laboratories by 5.0% during the 3rd quarter. IFP Advisors Inc now owns 614 shares of the company’s stock valued at $321,000 after purchasing an additional 29 shares during the period. AlphaStar Capital Management LLC purchased a new position in shares of IDEXX Laboratories in the third quarter worth approximately $262,000. Kintegral Advisory LLC boosted its holdings in shares of IDEXX Laboratories by 0.6% in the third quarter. Kintegral Advisory LLC now owns 5,115 shares of the company’s stock worth $2,671,000 after buying an additional 28 shares during the last quarter. Pension & Wealth Management Advisors Inc. bought a new stake in IDEXX Laboratories during the third quarter valued at approximately $29,000. Finally, Howard Capital Management LLC bought a new stake in IDEXX Laboratories during the third quarter valued at approximately $1,249,000. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

IDXX has been the subject of a number of research reports. KeyCorp assumed coverage on shares of IDEXX Laboratories in a report on Monday, October 12th. They set a “sector weight” rating for the company. Weiss Ratings raised shares of IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a research report on Thursday, October 8th. Citigroup upped their price objective on IDEXX Laboratories from $650.00 to $670.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 5th. UBS Group upped their price objective on IDEXX Laboratories from $620.00 to $670.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 5th. Finally, JPMorgan Chase & Co. decreased their target price on IDEXX Laboratories from $775.00 to $750.00 and set an “overweight” rating on the stock in a report on Friday. Seven equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $744.09.

IDEXX Laboratories Stock Performance

IDEXX Laboratories stock traded down $3.13 during midday trading on Monday, hitting $557.23. The stock had a trading volume of 155,436 shares, compared to its average volume of 568,739. IDEXX Laboratories, Inc. has a 52-week low of $500.61 and a 52-week high of $769.98. The company has a market capitalization of $43.90 billion, a PE ratio of 39.19, a P/E/G ratio of 2.99 and a beta of 1.55. The firm’s fifty day moving average is $534.22 and its two-hundred day moving average is $551.80. The company has a current ratio of 1.17, a quick ratio of 0.87 and a debt-to-equity ratio of 0.19.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings results on Tuesday, August 4th. The company reported $4.27 earnings per share for the quarter, beating the consensus estimate of $3.94 by $0.33. The business had revenue of $1.22 billion for the quarter, compared to the consensus estimate of $1.20 billion. IDEXX Laboratories had a net margin of 25.03% and a return on equity of 71.96%. The company’s revenue for the quarter was up 9.7% on a year-over-year basis. During the same quarter in the previous year, the firm earned $3.50 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. On average, research analysts forecast that IDEXX Laboratories, Inc. will post 14.81 EPS for the current year.

Insider Activity at IDEXX Laboratories

In other news, Director Lawrence D. Kingsley sold 2,203 shares of the firm’s stock in a transaction on Friday, September 4th. The shares were sold at an average price of $532.08, for a total transaction of $1,172,172.24. Following the sale, the director directly owned 9,568 shares in the company, valued at $5,090,941.44. This trade represents a 18.72% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 0.79% of the stock is owned by insiders.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) develops and provides diagnostic, information technology, and related products and services for the animal health and water testing markets. The company primarily serves veterinary practices, helping them diagnose and monitor diseases through laboratory tests, in-clinic analyzers, software, and digital practice-management solutions.

IDEXX’s companion animal offerings include hematology, chemistry, urinalysis, immunodiagnostics, and imaging-related products, along with reference laboratory services and veterinary software.